Financial Management Professionals Inc. Sells 236 Shares of ICON Public Limited (NASDAQ:ICLR)

Financial Management Professionals Inc. lowered its stake in ICON Public Limited (NASDAQ:ICLR) by 44.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 291 shares of the medical research company’s stock after selling 236 shares during the quarter. Financial Management Professionals Inc.’s holdings in ICON Public were worth $61,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ICLR. Steph & Co. raised its holdings in shares of ICON Public by 3.7% during the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after purchasing an additional 55 shares during the period. Arkadios Wealth Advisors grew its holdings in shares of ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after buying an additional 62 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its position in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after acquiring an additional 111 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of ICON Public stock opened at $198.11 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. ICON Public Limited has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a fifty day moving average of $209.71 and a 200-day moving average of $267.52. The stock has a market capitalization of $16.34 billion, a price-to-earnings ratio of 22.09, a price-to-earnings-growth ratio of 1.59 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.10 EPS. Equities research analysts expect that ICON Public Limited will post 13.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ICLR shares. The Goldman Sachs Group decreased their price target on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Citigroup dropped their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Barclays decreased their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.